194853-82-2

Basic information

• Product Name: 1-pyridin-4-yl-1,4-diazepane
• Synonyms: 1-pyridin-4-yl-1,4-diazepane
• CAS NO: 194853-82-2
• Molecular Formula: C₁₀H₁₅N₃
• Molecular Weight: 177.2462
• Mol File: 194853-82-2.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 324.5°C at 760 mmHg
• Flash Point: 150°C
• Appearance: /
• Density: 1.05g/cm³
• Vapor Pressure: 0.000245mmHg at 25°C
• Refractive Index: 1.534
• CAS DataBase Reference: 1-pyridin-4-yl-1,4-diazepane(CAS DataBase Reference)
• NIST Chemistry Reference: 1-pyridin-4-yl-1,4-diazepane(194853-82-2)
• EPA Substance Registry System: 1-pyridin-4-yl-1,4-diazepane(194853-82-2)

Safety Data

• Hazardous Substances Data: 194853-82-2(Hazardous Substances Data)

Usage

Description

1-pyridin-4-yl-1,4-diazepane, also known as 4-Pyridinyl-1,4-diazepane, is a chemical compound with the molecular formula C11H17N3. It belongs to the family of diazepanes, which are seven-membered heterocyclic compounds containing a nitrogen atom. This particular compound contains a pyridine ring, which is a six-membered aromatic heterocyclic ring containing nitrogen, and a diazepane ring, which is a seven-membered heterocyclic ring containing two nitrogen atoms. It is used in the pharmaceutical industry as a building block in the synthesis of various bioactive compounds. Additionally, its unique structure and properties make it potentially useful in medicinal chemistry for the development of new drugs.

Uses

Used in Pharmaceutical Industry:
1-pyridin-4-yl-1,4-diazepane is used as a building block for the synthesis of various bioactive compounds, contributing to the development of new drugs with potential therapeutic applications.
Used in Medicinal Chemistry:
1-pyridin-4-yl-1,4-diazepane is used in the field of medicinal chemistry for the development of new drugs, leveraging its unique structure and properties to create innovative pharmaceutical agents.

InChI:InChI=1/C10H15N3/c1-4-11-7-9-13(8-1)10-2-5-12-6-3-10/h2-3,5-6,11H,1,4,7-9H2

Upstream product

• 505-66-8 1,4-Diazacycloheptane 
• 1120-87-2 4-bromopyridin 
• 868065-23-0 4-(4-pyridyl)-1,4-diazepane-1-carboxylic acid tert-butyl ester 
• 112275-50-0 tert-butyl 1,4-diazepine-1-carboxylate 
• 626-61-9 4-Chloropyridine 

Downstream Products

• 492431-39-7 N-[5-chloro-1-[(2,4-dimethoxyphenyl)-sulphonyl]-3-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(4-pyridyl)homopiperazine-1-carboxamide 
• 220220-06-4 1-(4-nitrophenyl)-4-(pyridin-4-yl)-1,4-diazepane 
• 714249-12-4 ethyl ({[(7-cyano-2-naphthyl)methyl]{4-[4-(pyridin-4-yl)-1,4-diazepan-1-yl]phenyl}amino}sulfonyl)acetate 
• 220220-31-5 7-[({4-[4-(pyridin-4-yl)-1,4-diazepan-1-yl]phenyl}amino)methyl]-2-naphthonitrile 

Relevant articles and documents

Discovery and structure-activity relationship of thienopyridine derivatives as bone anabolic agents

A cell-based assay was performed for the discovery of novel bone anabolic agents. Alkaline phosphatase (ALPase) activity of ST2 cells was utilized as an indicator of osteoblastic differentiation, and thienopyridine derivative 1 was identified as a hit compound. 3-Aminothieno[2,3-b]pyridine-2-carboxamide was confirmed to be a necessary core structure for the enhancement of ALPase activity, and then optimization of the C4-substituent on the thienopyridine ring was carried out. Introduction of cyclic amino groups to the C4-position of the thienopyridine ring improved the activity. Especially, N-phenyl-homopiperazine derivatives were found to be strong enhancers of ALPase among this new series. Furthermore, 3-amino-4-(4-phenyl-1,4-diazepan-1-yl)thieno[2,3-b]pyridine-2- carboxamide (15k) was orally administered to ovariectomized (OVX) rats over 6 weeks for evaluating the effects on areal bone mineral density (aBMD), and statistically significant improvements in aBMD were observed from the dosage of 10 mg/kg/day.

Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use

The invention relates to compounds of formula: and also to the salts thereof with mineral or organic acids, and the solvates and/or hydrates thereof, with affinity for and selectivity towards the arginine-vasopressin V1b receptors and/or for the ocytocin receptors and, furthermore, for certain compounds, affinity for the V1a receptors. The invention also relates to the process for preparing them, to the intermediate compounds of formula (IV) that are useful for preparing them, to pharmaceutical compositions containing them and to their use for preparing medicinal products.